ANN ARBOR, Mich., – May 28, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”)  announces an update on the commercialization of its BAM-1 recombinant spider silk production hybrids.

First made public in February of 2024, as part of the Company’s now successfully concluded spring production trails, the BAM-1 hybrid is the latest development in recombinant spider silk production technology.

Kraig Labs’ BAM-1 production platform has proven to be the most robust and resilient production system for commercial-scale production of recombinant spider silk. What sets the BAM-1 system apart from previous developments is the strong and robust commercial genetic backbone that these strains were developed into.

The BAM-1 hybrid system represents a major advancement in the production capacity for the Company’s spider silk commercialization efforts. This new production platform integrates the Company’s spider silk technologies into production-ready silkworm strains. 

BAM-1 is a silk production system developed by Kraig Labs to serve as an integration platform for its recombinant spider silk technologies. The BAM-1 hybrids produce Dragon Silk^TM, one of the Company’s major recombinant spider silk technology breakthroughs. Kraig Labs developed Dragon Silk to blend spider silk’s incredible physical and chemical properties with commercially scalable technology leveraging mundane silk production infrastructure.

The Company’s merger of the BAM-1 hybrid manufacturing technologies with the cutting-edge bio-engineering of Dragon Silk has created what Kraig Labs believes to be the most advanced and scalable spider silk production system in existence.

“The BAM-1 hybrids have been a huge success, and they are unlocking the powerful potential of our spider silk technologies,” said Kim Thompson, Founder and CEO of Kraig Labs. “The BAM-1 hybrids have proven to be a scalable and reliable platform for Dragon Silk manufacturing. As we bring the next generation of pure spider silk technologies to market, the BAM-1 production system will serve to rapidly accelerate their transition to commercialization.”

Due to the success of its spring production trials, the Company remains ahead of schedule for its 2024 production season. It expects to provide further details of that production expansion in the coming weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 20, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed its analysis of its spring spider silk production trials. Kraig Labs is rapidly integrating lessons learned from the production trials to establish a strong foundation for production expansion in 2024.

The Company identified key input parameters in five specific aspects of its production operations that contributed to the exceptional results in the spring trials. Through the identification and close monitoring of these inputs, Kraig Labs expects that it will be able to sustain its projected  growth trajectory, targeting metric ton levels of spider silk production in 2024.

These process enhancements range from major advancements in our silkworm genetics introduced in Q1, to minor modifications in feeding cycles, feedstock selection, and facility layout. When combined, these process improvements resulted in the largest, strongest, and most robust silkworms and recombinant spider silk cocoons that Kraig Labs has ever produced.

While the details of these operational advancements will remain the Company’s trade secrets, these enhancements broadly fall into five unique categories: nutrition, climate, genetic, staffing, and rearing conditions. Kraig Labs made significant advancements in each of these areas during the spring trials under the guidance of celebrated sericulture expert, Dr. Nirmal Kumar. 

“The amazing successes of the spring production trials demonstrate that we have unlocked the key to metric ton level spider silk production,” said Founder and CEO, Kim Thompson. “Our team is ready. Our silkworm genetics are ready. Now is the time to build out the production capacity and scale our operations to meet the demand for spider silk.”

With these operational improvements in place, the Company has elected to accelerate its launch of larger-scale operations and accelerate its production schedule. The next generation of BAM-1 spider silk hybrids are now prepared for launch nearly a full month ahead of schedule. Kraig Labs will continue to keep its shareholders updated as the BAM-1 hybrid production expansion continues and the Company brings additional production capacity online.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 15, 2024 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), announces that it remains proud to share information relating to its recent progress and the resounding success of the spring production trials. The Company has been and will continue to be active in its investor awareness program to ensure that our shareholders and the public are updated with our accomplishments and plans for the immediate future.   

At the request of OTC Markets Group, the Company has reviewed its investor relations (IR) program and recent publications to ensure that it is holding its IR program and all vendors to our strict guidelines and expectations. The Company was made aware on May 13 of an editorial on 24/7 Market News highlighting recent advancements in spider silk production and the potential impacts on the market. This publication was drafted by a third-party contractor hired by the Company’s IR team and included a full disclosure of financial compensation as required. While the Company did not have editorial control over the recent publication on 24/7 Market News, the documents that we have reviewed, in our opinion, are truthful and factual.

Our policy requires our IR providers to fully and completely disclose any compensation they receive and that all information is factual, or if an honestly held opinion, is stated as an opinion. Beyond the strict legal compliance our IR providers maintain, we have recently requested that they eliminate suggestions about how our operational breakthroughs may impact market responses.

Kraig Labs has long-standing and productive working relationships with Hansel Capital and Karolus Maximus Kapital. These two firms provide the Company with support for shareholder inquiries and investor relations services. The Company has hired and directed these two supporting firms to create and provide shareholders and the public with updates and news on the Company’s progress. We are very aware of the added burden our strict compliance policies place on these contractors and thank them for their work and efforts.

With a series of production breakthroughs in the first quarter and early second quarter of 2024, the Company has significantly increased communication efforts to share these successes with its shareholders and the markets. The Company remains committed to delivering its vision of metric-ton scale manufacturing of spider silk.

As an SEC-compliant, fully reporting public Company, we hold the highest standards for reporting and public disclosure. No Company officers, insiders, control persons, or contracted third-party providers have traded in the Company’s common stock over the last 90 days. No shares of the Company’s common stock have been issued to any party in the last 90 days.  The Company’s CEO did acquire one restricted non-tradable preferred share in April 2024. As a part of its reporting requirements, all stock sales, convertible instruments, registered offerings, or private placements have been reported in our public filings found on the Company’s website or through the SEC EDGAR system.

Our shareholders can expect us to continue to work diligently to improve our fundamentals and share the Company’s progress through all available and appropriate channels.

Our recent announcements regarding the success of the spring production trials were a major milestone for the Company and represent a strong shift to scaled production. The Company believes that the improvements in our fundamentals and spreading of the word of these positive changes, including our advancements in production through our website, press release, and investor relations providers, have significantly impacted our market dynamics. This is an exciting time for Kraig Labs, and we believe there is a bright future for the Company and recombinant spider silk. 

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 13, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it is pursuing a possible business expansion into Cambodia to support the rapid growth and diversification of its recombinant spider silk production.

The Company’s founder and CEO, Kim Thompson, together with a joint team from Kraig Labs and Prodigy Textiles, recently surveyed potential production locations in Cambodia. During the survey the team identified areas of the country which would be suitable for production. An added draw to Cambodia is its proximity to existing Kraig Labs operations, its business-friendly environment, and specific opportunities identified by the team.

With the overwhelming success of the Company’s spring production trials and the rapid expansion of production planned for this year, management is working to add additional potential capacity and diversify its production base.

“Cambodia would be a strong complement to our expanding production operations,” said Thompson. “Diversification and expansion of our operations has been a core element of our business model. With the success of the spring production trials, we are now in a position to activate this next expansion stage.”

Production at the Company’s existing facilities is expected to continue to increase exponentially over the next two quarters, with the target of one metric ton before year’s end. Thompson and Dr. Nirmal Kumar will continue to closely monitor each stage of expansion to ensure the Company continues to build on the successes of the spring trials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – May 6, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that the spring production trials of the Company’s new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness.

Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the Company’s BAM-1 recombinant spider silk hybrids are ready for rapid production expansion. Simply stated, this has been the most fruitful and successful production cycle in the Company’s history.

Renowned sericulture expert and Kraig Labs executive consultant, Dr. Nirmal Kumar, oversaw the production cycle from start to finish, including rearing and selective breeding. Careful and meticulous testing throughout the entire production trial demonstrated that the BAM-1 parental lines were the strongest and most resilient lines Kraig Labs has ever developed.

Observation and screening conducted throughout all phases of production exceeded all expectations for health and vigor within the colony. Not a single instance of disease or infection was detected at any point during the entire cycle. This result surprised local silkworm experts observing the trials. Working with mundane silkworms, they had never experienced an entire production cycle from egg to egg without any disease in a batch of thousands of silkworms. 

Under the guidance of Dr. Nirmal Kumar and through a meticulous, statistically-based selective breeding protocol, the parental strains for the BAM-1 hybrid were further optimized during the production cycle. The enhancements to the parental lines from this careful breeding program were designed to deliver larger cocoons with improved reeling characteristics and higher yields.   

“I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines,” Dr. Nirmal Kumar, stated. “The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can’t be matched. The results of these trials exceeded our expectations. We are now on a solid foundation to scale production of the BAM-1 hybrid to metric ton levels.”

 “The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded,” said Company founder and CEO, Kim Thompson. “This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries.”

Thompson and Dr. Nirmal Kumar have spent the last two months directly overseeing these trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company’s immediate plans. Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company’s transition from a technology developer to a large-scale spider silk manufacturer.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 29, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), announces today that it has signed key agreements with the Lam Dong Agro-Forestry Research Experiment Center (“LAREC”), the sericulture authority in central Vietnam, pertaining to the rearing and breeding of the Company’s specialized silkworm.

Within these agreements, Kraig Labs outlined its operational plans for expansion. These agreements outline a collaborative working effort between the Company and the LAREC to integrate the Company’s silk technologies.

Under the terms of the agreements, the LAREC will provide insights and assistance in the selective breeding of the Company’s BAM-1 parental strains tailored for the local climate and rearing conditions. The LAREC will also raise one generation of the BAM-1 strain at LAREC facilities and deliver the resulting eggs back to Kraig Labs for use in its operations.  

This definitive agreement further strengthens the collaboration between Kraig Labs and governmental agencies. The agreement builds on the Memorandum of Understanding that the Company announced on January 30, 2024. 

“Building these key working relationships is near the top of our agenda, as we expand and grow. We see this agreement as an opportunity to work together to integrate new technologies and deepen our ties in the region,” said Company founder and CEO, Kim K. Thompson. “Forming these working agreements with key sericulture leaders and governmental agencies in South East Asia is a key piece of our unfolding expansion,” continued Thompson, “We look forward to seeing this relationship grow as we work to strengthen our ties in the region. Simultaneously, our operations are exceeding expectations, with the spring production trials now near completion. We have consistently hit our marks over the last two quarters and will soon be ready to enter the next phase of our business plan.”

Thompson remains in South East Asia with renowned sericultural expert, Dr. Nirmal Kumar, overseeing operations as the Company completes the spring production trials and transitions into phase two of its production plan.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 22, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial. Kraig Labs has successfully produced cocoon at rates that exceeded all expectations and control parameters for these trials.

Under the supervision and guidance of a top independent sericulture expert, Dr. Nirmal Kumar, whom the Company brought in to oversee these trials, Kraig Labs has now finished the critical rearing stage for both parental strains of the BAM-1 hybrid. Each parental strain was divided into two batches, creating a total of four separate production trial groups. The result was an absolute success, with all four production batches achieving excellent growth rates and nearly perfect cocooning.

“I am very impressed with the robustness of the BAM-1 parental lines,” said Dr. Nirmal Kumar. “The colony has exhibited perfect health and grown very quickly. The team’s rearing skills are rapidly advancing, and they are ready to increase production. Based on what I have observed from rearing this first generation, I expect that the Company will have a very successful production scale-up.”

The launch of these operations, after careful preparation and under the supervision of a renowned sericultural expert, demonstrated that the BAM-1 parental lines meet the performance and robustness necessary for large-scale production. With the successful completion of cocooning, the Company can confirm that the BAM-1 line has proven it is ready for scale-up. Over the next two weeks the Company will collect the moths from these cocoons to breed the next generation of production hybrid silkworms and conclude the critical parental line trial.

Meticulous testing and screening of the silkworms throughout the entire rearing cycle proved that the BAM-1 lines are the strongest, most robust recombinant spider silk strains the Company has ever produced. With zero observation of disease within any of the four production batches, the Company and its consultants are now prepared to accelerate the drive to reach metric-ton-level production.

“The BAM-1 hybrids have exceeded our expectations thanks in part to our team, our outside consultants, and Dr. Nirmal Kumar’s guidance,” said Company founder and CEO, Kim Thompson. “Initial results have shown faster growth rates, nearly perfect cocooning rates, and larger cocoon size than we have seen even in our own R&D center. We are in an entirely new ball game now. 

The current production trial will continue to run for two or three weeks. Additional data on each of the four production batches is being collected and processed. “We are 85% to 90% through the trial of the parental strains, and every single batch of our new strains sailed through what we expected to be the toughest challenges,” continued Thompson. “Even in advance of the conclusion of the trials, I am happy to report that our two-year program of acclimation to the production environment appears to have been achieved.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 15, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that the spring production trials for the new BAM-1 hybrid have begun and are well on track to meet the Company’s expectations and timeline.

The Company successfully launched the production trials of BAM-1, its newest and most robust recombinant spider silk production silkworm hybrid, on time and in line with its production roadmap. The Company’s CEO remains in Asia to directly oversee the production trial of the BAM-1 parental strains and monitor their performance.

Following health screenings and daily monitoring of the colony, the Company can now report that this is currently the strongest and healthiest batch of silkworms it has ever produced in Southeast Asia. Specifically, disease screening by the Company and its consultants has shown zero instances of disease in the colony. This can be attributed in part to the improved genetics and robustness of the BAM-1 parental strains. Moreover, significant credit for this improved performance must also be attributed to the knowledge and rearing technology transfer that Dr. Nirmal Kumar, of India, has brought to the team.

“Our team invested heavily in improving the robustness of our production recombinant spider silk strains based on hard lessons learned and the testing data collected in 2023. With the support and added insight Dr. Nirmal Kumar is providing, we are on track for the most productive and successful spider silk production year in the Company’s history,” said founder and CEO, Kim Thompson. “Dr. Nirmal Kumar will be on the ground working with our team through this entire trial of the parental strains in order to lay a solid foundation for all future production. I believe we are in the midst of a breakout year for the Company as we continue to hit our marks on the business plan and deliver on our vision for commercial scale spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 8, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has signed a landmark agreement with the Vietnam Sericulture Association (“VSA”). As part of this agreement, the Company disclosed its production plans and schedule for the next twenty-four months to the VSA to obtain cooperation in reaching its production targets. This agreement establishes a collaborative working effort between the Company and the VSA, something the Company has been actively working towards for some time.

Under the terms of the agreement, in addition to support and advice on production logistics, the VSA has agreed to assist the Company in obtaining formal intellectual property registration of its BAM-1 hybrid silkworm strain in Vietnam. 

This definitive agreement strengthens the collaboration between the Company and the VSA, building on and expanding the Memorandum of Understanding announced on January 30, 2024. This landmark agreement establishes the framework and much of the logistical support needed for the Company to achieve metric-ton levels of production. 

“This agreement is the culmination of many years of work with various governmental and non-governmental agencies to demonstrate our technology and its potential,” said Company founder and CEO, Kim K. Thompson. “This new relationship with the VSA underlines our commitment to South East Asia and, we believe, significantly strengthens our position as we scale up production. With this agreement finalized, we are now working jointly with a capable partner to see that vision fulfilled.”

“We have been following developments at Kraig Labs for many years and are very happy now to be working directly with them,” said Dr. Le Quang Tu, President of the Vietnamese Sericulture Association. “We believe that Kraig’s technology will have a significant positive impact on our industry. They have applied a thoughtful, step-by-step approach. Now, we will take a step together.”

The Company’s CEO remains in Vietnam, overseeing operations directly. Kraig Labs anticipates that Thompson will provide additional announcements and updates regarding the Company’s accelerating progress over the coming weeks. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – March 28, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute (“RPI”).

Researchers at RPI published a paper in Microbial Cell Factories outlining a new and novel method of creating spider silk protein from waste plastics.

This project used a new strain of Pseudomonas bacteria capable of converting depolymerized polyethylene into targeted recombinant proteins. While this work is in the early stages, it shows the potential for this process to create spider silk-like proteins from partially decomposed plastics.

Plastic wastes continue to accumulate globally, resulting in disposal and recycling challenges as well as increased levels of microplastics showing up in our food and water supplies. Creating useful and easily biodegradable silk proteins from these materials could help alleviate this growing concern.

“I am encouraged to see the continued focus and breadth of research developing in the field of spider silk technologies,” said CEO and Founder, Kim Thompson. “While this approach using bacteria doesn’t directly create silk fibers, the potential impact of creating technologies to address the growing plastic waste and convert that into useful and biodegradable materials is very exciting. We congratulate the team at Rensselaer Polytechnic Institute for their work. While our production methods have no direct connection to the work at RPI, the commonality is environmentally friendly spider silk through molecular biology.”

Kraig Labs’ recombinant spider silk production model utilizes traditional silk production systems involving planting mulberry trees to harvest and feed the leaves to silkworms. The Company’s specialized silkworms have been scientifically enhanced through molecular biology to create recombinant spider silk cocoons that are reeled to produce spider silk yarns and fabrics. Kraig Labs is currently working to expand its spider silk production footprint. The Company’s CEO and its leading sericulture expert are currently in Southeast Asia working to prepare for the launch of the Company’s spring 2024 production trials and the 2024 silk production season.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com